Group 1: Strategic Overview - New Mile Health Group has transitioned from a single medical focus to a comprehensive health industry model, integrating medical care, elderly care, pharmaceuticals, and insurance [3] - The company identifies "medical + insurance" as a key solution to address the challenges of an aging population, particularly in terms of medical capacity and payment ability [3][4] Group 2: Market Opportunities - Policy support, such as the Sanming medical reform and emphasis on commercial insurance collaboration, has created new growth opportunities for managed healthcare [5] - Increased public health awareness and the need for differentiated health management services are driving demand for managed healthcare solutions [5] Group 3: Collaboration with Aixin Life - Aixin Life's strategic partnership with New Mile Health Group aims to leverage the latter's extensive hospital management experience to overcome industry barriers [3][4] - The collaboration focuses on integrating medical resources with insurance capabilities, enhancing customer acquisition and retention through tailored insurance products [6][7] Group 4: Business Performance - As of now, New Mile Health has nearly 5,000 members, generating approximately 3 million yuan in premium income and 17 million yuan in hospital revenue [5] - The conversion rate for insurance clients at New Mile's hospitals is 50%, significantly higher than traditional sales channels, with customer satisfaction exceeding 95% [11] Group 5: Future Outlook - The company plans to expand its managed healthcare model to include a broader demographic, focusing on both healthy and chronic patients [14] - Emphasis will be placed on preventive care, screening, and rehabilitation, moving beyond traditional treatment models to create a comprehensive health management ecosystem [14]

Core Viewpoint - The company held its 2024 annual performance briefing, where it engaged with investors and addressed various inquiries regarding its business strategies and performance metrics. Group 1: Company Performance - In 2024, the company achieved total revenue of 1.349 billion yuan, representing a year-on-year growth of 16.93% [6] - The net profit attributable to shareholders was 113 million yuan, an increase of 11.54% year-on-year [6] - The company's proprietary drug business generated 283 million yuan in revenue, marking a 44.31% increase compared to the previous year [6][7] Group 2: Business Strategy - The company is focused on a management-style medical strategy, which has led to a revenue growth of 25%-30% in its pharmaceutical and medical services sectors [4] - The company aims to enhance its digital health management services, covering the entire patient lifecycle, to improve drug sales and patient compliance [4][7] - The company plans to optimize its liver disease patient management system in response to the "Healthy China 2030" initiative [4] Group 3: Market Position and Future Outlook - The domestic market accounted for 36.72% of revenue, while the international market contributed 63.28% in 2024 [4] - The company is committed to becoming a professional and international management-style medical group, focusing on liver cancer screening and management [4][7] - The company anticipates that the market for its products will enter a rapid growth phase following the approval of the MASH indication by the FDA [4][8] Group 4: Product and Service Development - The company has developed a full-cycle management solution for liver disease, integrating screening, diagnosis, and treatment [4][7] - The FibroScan Go and box products have been installed in 651 units globally, becoming new revenue growth points for the company [7] - The company is enhancing its marketing strategies for its proprietary drugs and expanding its e-commerce channels to sustain high growth rates [6][7]

Group 1: Company Performance and Financials - In 2024, the company achieved total revenue of CNY 1.349 billion, a year-on-year increase of 16.93% [10] - The net profit attributable to shareholders was CNY 113 million, up 11.54% year-on-year [10] - The revenue contribution from the equipment and technology segment was approximately 68%, while the pharmaceutical segment contributed about 28%, and medical services and others accounted for around 4% [8] Group 2: Product and Market Strategy - The company’s self-owned pharmaceutical business generated revenue of CNY 283 million in 2024, reflecting a growth of 44.31% [7] - The sales channels for pharmaceuticals, particularly e-commerce, showed significant growth, with increases of 87.44% and 145.37% respectively [10] - The company aims to enhance its market penetration globally, focusing on management-style medical services and improving patient management [10] Group 3: Future Outlook and Strategic Initiatives - The company plans to submit its products for FDA approval in Q1 2026, with a focus on improving financial conditions through increased commercial activities [2] - The management strategy includes a dual approach of consolidating traditional sales channels while developing digital health management services [8] - The company is committed to optimizing the liver disease patient management system and enhancing early screening strategies [12] Group 4: Risk Management and Cost Control - The company has established a risk assessment management system to identify and respond to potential risks [5] - In 2024, the pharmaceutical gross margin increased to 47.71%, a rise of 9.46 percentage points year-on-year [15] - Measures to control costs include managing the procurement of key raw materials like Cordyceps and ensuring operational efficiency [16]

Financial Performance - In 2024, the company achieved a revenue of CNY 3.799 billion, a decrease of 2.95% compared to 2023 [3] - The medical services sector generated CNY 3.05 billion, while the pharmaceutical sector contributed CNY 750 million [3] - Net profit attributable to shareholders was CNY 115 million, marking a significant increase of 296.13% [3] - Cash flow from operating activities reached CNY 439 million, an increase of 36.64% year-on-year [3] - As of year-end, total assets amounted to CNY 6.677 billion, with net assets at CNY 1.985 billion [3] - The weighted average return on equity improved to 5.16%, up by 4.02 percentage points from 2023 [3] - In Q1 2025, revenue was CNY 796 million, with a net profit of CNY 25.65 million [3] Operational Strategies - The company is focusing on a "medical + pharmaceutical" dual-driven strategy to enhance brand image and market influence [4] - Plans to expand hospital capacity and improve service quality through specialized committees and management practices [4] - The pharmaceutical sector aims to increase revenue through R&D, acquisitions, and channel reforms [4] - The company is actively pursuing mergers and acquisitions to enhance business scale and performance [4] Insurance and Revenue Structure - In 2024, insurance revenue accounted for 52% of total income, with a payment cycle of 2-3 months [4] - The company is implementing strategies to improve insurance settlement rates amidst existing pressures [4] - The introduction of DRG 2.0 in several hospitals aims to manage costs and enhance service quality [6] Technological Integration - All hospitals have adopted DeepSeek for AI applications, enhancing operational efficiency and patient data management [11] - The AI implementation has improved patient understanding of their health status and increased the quality of medical records [11] Market Position and Future Outlook - The price reduction of the Du Yi Wei product line by approximately 34% post-collection has led to a decrease in revenue but minimal impact on overall profit [14] - The company holds over 80% market share for the Du Yi Wei series, indicating strong product recognition and quality [14] - Future plans include optimizing product structure and seeking acquisitions to enhance market competitiveness [14] Asset Management - The company is planning continuous asset injections from the controlling shareholder, with a focus on compliance and market conditions for pricing [15] - The strategy aims to leverage favorable regulatory policies for mergers and acquisitions [15]

Financial Performance - In 2024, the company achieved operating revenue of 1.349 billion yuan, a year-on-year increase of 16.93% [1] - The net profit attributable to shareholders was 113 million yuan, up 11.54% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 118 million yuan, reflecting a growth of 19.33% [1] - In Q1 2025, the company experienced a slight increase in operating revenue, primarily due to a high base from the previous year, while profits declined due to foreign exchange losses and stock incentive expenses [1] Strategic Initiatives - The company is advancing a "product + service" dual-driven model, enhancing traditional pharmaceutical sales while establishing digital health management services to improve patient adherence and sales of key products [2] - The company is committed to a managed care service model, focusing on liver cancer screening standards and developing comprehensive management solutions from screening to treatment [2] - The company aims to increase liver disease detection and treatment rates while ensuring a win-win situation for insurance, doctors, and patients [2] Research and Development - A national major science and technology project focusing on the prevention and clinical evaluation of primary liver cancer has been launched, involving collaboration with 11 authoritative medical institutions [3] - The project aims to provide comprehensive health solutions for 447 million chronic liver disease patients in China [3] Product Development - The FibroScan liver elastography device has been recognized as the "best" by American guidelines, with over 5,200 clinical research publications supporting its efficacy [4] - By the end of 2024, the company had installed 651 units of FibroScan Go and box globally, with plans to expand its clinical application scenarios in 2025 [4] - The company has established itself as a leader in the fatty liver field, with significant research demonstrating the effectiveness of its products in reducing liver cancer incidence and mortality [4]